BeiGene, Ltd.

NasdaqGS:BGNE Voorraadrapport

Marktkapitalisatie: US$24.8b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BeiGene Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Oyler

Algemeen directeur

US$18.9m

Totale compensatie

Percentage CEO-salaris4.6%
Dienstverband CEO14.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn2.5yrs
Gemiddelde ambtstermijn bestuur4.5yrs

Recente managementupdates

Recent updates

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19
Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17
Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24
A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Analyse CEO-vergoeding

Hoe is John Oyler's beloning veranderd ten opzichte van BeiGene's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$524m

Mar 31 2024n/an/a

-US$784m

Dec 31 2023US$19mUS$871k

-US$882m

Sep 30 2023n/an/a

-US$959m

Jun 30 2023n/an/a

-US$2b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$18mUS$800k

-US$2b

Sep 30 2022n/an/a

-US$2b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$17mUS$740k

-US$1b

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$14mUS$696k

-US$2b

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$1b

Mar 31 2020n/an/a

-US$1b

Dec 31 2019US$13mUS$675k

-US$949m

Sep 30 2019n/an/a

-US$829m

Jun 30 2019n/an/a

-US$665m

Mar 31 2019n/an/a

-US$737m

Dec 31 2018US$28mUS$650k

-US$674m

Sep 30 2018n/an/a

-US$505m

Jun 30 2018n/an/a

-US$243m

Mar 31 2018n/an/a

-US$147m

Dec 31 2017US$10mUS$515k

-US$93m

Compensatie versus markt: De totale vergoeding ($USD 18.93M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).

Compensatie versus inkomsten: De vergoeding van John is gestegen terwijl het bedrijf verliesgevend is.

CEO

John Oyler (56 yo)

14.8yrs

Tenure

US$18,925,730

Compensatie

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
John Oyler
Co-Founder14.8yrsUS$18.93mgeen gegevens
Xiaobin Wu
President & COO6.4yrsUS$11.00mgeen gegevens
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder14.8yrsUS$4.42mgeen gegevens
Chan Lee
General Counsel & Senior VP2.3yrsUS$4.05mgeen gegevens
Wang Lai
Global Head of R&Dno dataUS$7.32mgeen gegevens
Aaron Rosenberg
CFO & Principal Financial Officerless than a yeargeen gegevensgeen gegevens
Titus Ball
VP & Chief Accounting Officerless than a yeargeen gegevensgeen gegevens
Liza Heapes
Head of Investor Relationsno datageen gegevensgeen gegevens
Yang Ji
Chief Compliance Officerless than a yeargeen gegevensgeen gegevens
Yan Qi
Senior VP & Head of Public Affairs - Greater China3.8yrsgeen gegevensgeen gegevens
Jason Radford
Senior Vice President of Strategy & Corporate Development1.7yrsgeen gegevensgeen gegevens
Mark Lanasa
Senior VP & Chief Medical Officer for Solid Tumors2.7yrsgeen gegevensgeen gegevens

2.5yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BGNE wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
John Oyler
Co-Founder14yrsUS$18.93mgeen gegevens
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder8.7yrsUS$4.42mgeen gegevens
Steven Young
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board3.5yrsgeen gegevensgeen gegevens
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee9.5yrsUS$481.92kgeen gegevens
Donald Glazer
Independent Non-Executive Director11.7yrsUS$480.80kgeen gegevens
Corazon Sanders
Independent Non-Executive Director & Member of Scientific Advisory Committee4.2yrsUS$501.55kgeen gegevens
Anthony Hooper
Independent Non-Executive Director4.8yrsUS$513.15kgeen gegevens
Shalini Sharp
Directorless than a yeargeen gegevensgeen gegevens
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director2.7yrsUS$491.67kgeen gegevens
Olivier Brandicourt
Independent Non-Executive Directorless than a yeargeen gegevens0%
$ 0
Ranjeev Krishana
Independent Lead Director10yrsUS$487.05kgeen gegevens
Margaret Han Dugan
Member of Scientific Advisory Board & Independent Non-Executive Director2.7yrsUS$510.55kgeen gegevens

4.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BGNE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).